Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
Approval based on the positive GLISTEN phase III trial with regulatory reviews underway in the EU, UK, Canada and China

Take Your Experience to the Next Level

New

Download our mobile app for a faster and better experience.

Google Play
App Store

Comments

0
U

Join the discussion

Sign in to leave a comment

0:000:00